28/09/2026

EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

$4.3M NON-DILUTIVE R&D TAX INCENTIVE REFUND RECEIVED

Highlights

- **$4.3 million cash refund** received under the Australian Government's R&D Tax Incentive program for FY2026 eligible activities.
- **Additional non-dilutive funding** strengthens EMVision's financial reserves, which include a last reported cash position of $17.1m and remaining grant funding of $4.6m (as at 30 June 2026).
- **Eligible activities** spanned clinical, engineering and product development programs across both the emu™ and First Responder devices.

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company") is pleased to advise it has received a $4.3 million cash refund under the Australian Federal Government's R&D Tax Incentive program in relation to eligible research and development activities undertaken during the financial year ended 30 June 2026.

FY2026 was EMVision's most active development year to date. Eligible activities spanned the clinical programs for both devices: the emu™ Pivotal (Validation) Trial to support FDA clearance, recruiting at leading US and Australian stroke centres including Mayo Clinic, UCLA, Memorial Hermann, Mount Sinai, Royal Melbourne Hospital, Liverpool Hospital and Princess Alexandra Hospital; and the First Responder program, which has successfully completed aeromedical and in-field feasibility and usability studies.

The refund includes eligible overseas expenditure associated with the emu™ Pivotal Trial and related market access activities, in accordance with the Company's Advance Overseas Finding.

The R&D Tax Incentive provides eligible Australian companies with a cash refund for qualifying research and development, and remains an important source of non-dilutive funding for EMVision. The Company expects to continue to access the program for eligible FY2027 activities.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

About Stroke

Stroke is a medical emergency that occurs when blood flow to part of the brain is interrupted, either by a blocked vessel (ischaemic stroke) or bleeding into the brain (hemorrhagic stroke). The resulting lack of oxygen and nutrients can rapidly damage brain tissue, leading to disability or death if not treated promptly. Different stroke types require different types of care. Early recognition and fast access to diagnosis and appropriate care are critical, as timely intervention can significantly improve outcomes. EMVision is working to make rapid stroke diagnosis possible at the point of care, wherever the patient is.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.